The Pathology and Biobanking Core (PBC) has supported the efforts of the Baylor College of Medicine Breast SPORE for 26 years, offering comprehensive pathology services to SPORE investigators and others. All projects in this SPORE application propose the use of human biospecimens in assay development and for retrospective and/or prospective clinical trials, and this shared resource core is structured to meet the demands for high-quality, centralized banking and distribution of tissue specimens within this context. We have expertise and dedicated personnel for all routine histological studies, immunohistochemistry, immunofluorescence, tissue microarray preparation, and macro/micro-dissection techniques. Additionally, the Core supports advanced microscopy and digital imaging capability. All projects will also benefit from our recent expansion of state-of-the art molecular diagnostic platforms and high-complexity assay development, including quantitative PCR, microfluidics-based digital droplet PCR (ddPCR), next generation sequencing (NGS). The Core will provide the following services to projects and integration with other cores in this proposal: 1) a centralized resource to acquire, store, and utilize human biospecimens for cancer research; 2) To coordinate and manage the pathology activities of the SPORE, and ensure that Project Investigators have ready access to specialized pathology expertise and interpretation; and 3) to design and validate biomarker-based tests (genomic and/or proteomic) that support all project stages, including clinically-validated and reported assays for SPORE- based clinical trials. The SPORE benefits from integrated interactions between components, and this Core will work closely with other cores, particularly the Informatics and Statistics Core (ISC) for project design and correlative analyses. Further we will collaborate with the ISC to assist with selection and implementation of biospecimen repository, tracking and management software that spans all SPORE components. We will work with the Administration and Advocacy Core in management of laboratory resources and assist Career Development trainees with education in assay development and experimental analysis. The Core will assist proposed and funded Pilot Studies with exploratory assay design and technical validation support. The Pathology and Biobanking Core Laboratory is seeking both CLIA- and CAP-certification to meet Precision Medicine initiatives of this SPORE at Baylor College of Medicine.
The Pathology and Biobanking Core seeks to improve the lives of breast cancer patients by facilitating novel translational biomarker discovery into the development and validation of clinical assays. This Core serves as a centralized repository for biospecimen acquisition and use, management of the histopathology activities of each SPORE project, and the development and validation of biomarker-based molecular testing that supports all stages of SPORE project development.
|Zhao, Na; Cao, Jin; Xu, Longyong et al. (2018) Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128:1283-1299|
|Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292|
|Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38|
|Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42|
|Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254|
|Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740|
|Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34|
|Niravath, Polly; Chen, Bingshu; Chapman, Judy-Anne W et al. (2018) Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer 18:78-87|
|Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26|
|Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134|
Showing the most recent 10 out of 28 publications